EMERGENCY LINE: +603 7620 7979 / +603 7787 2992
logo beacon hospital
lutetium 177-psma, radionuclide therapy, beacon hospital, syringe, injection

What is Lutetium-177 (Lu-177) PSMA Therapy?

Lutetium-177 PSMA therapy is used to treat patients with advanced prostate cancers particularly those that have become resistant to the standard systemic treatments. Prostate cancers that have spread to other sites of the body expresses a unique substance on their cell surface known as Prostate Specific Membrane Antigen.

Lu-177 tagged together with the PSMA will specifically attach itself to cells with high expression of PSMA thus enabling the delivery of high doses of targeted radiation therapy while sparing the healthy normal tissues nearby.

Early clinical studies evaluating the safety and efficacy of Lu-177 PSMA therapy have demonstrated promising results with a significant proportion of men with advanced metastatic resistant prostate cancer, who have failed other treatment options, responding clinically to Lu177-PSMA.

The benefits of this targeted radionuclide therapy may include shrinkage of tumours, a reduction in blood PSA (Prostate Specific Antigen) level, improvement in symptoms such as pain and a general improvement in overall well-being.

Information

Visiting Hours:
10:00 – 22:00
General Line:
+603 7620 7979 +603 7787 2992
Consultants Appointment Line:
+603 7118 7878 +6012 328 6913
Email:
info@beaconhospital.com.my
Career Enquiries / HR:
joinus@beaconhospital.com.my
logo beacon hospital

Beacon Hospital Sdn. Bhd.

200301019556 (621976-D)
1, Jalan 215, Seksyen 51,
Off Jalan Templer,
46050 Petaling Jaya, Selangor.

Subscribe to Our Newsletter

Stay up-to-date with the latest healthcare trends, expert advice and latest events at Beacon Hospital.

Subscribe to Our Newsletter

Stay up-to-date with the latest healthcare trends, expert advice and latest events at Beacon Hospital.
© 2025 Beacon Hospital (寶康医院). SDN. BHD. 200301019556 (621976-D) | (KKLIU 3340/2025)